Weak US stock markets pulled European equities down on Monday. The EuroStoxx 50 extended losses in the afternoon to close 0.60 percent lower at 6,348.35 points. London's FTSE 100 recorded a decline of 0.09 percent to 10,892.93 points. Zurich's SMI gained 0.57 percent to finish at 15,192.58 points following an earlier record high.
Technology shares suffered heavy losses on both sides of the Atlantic. As the New York tech index Nasdaq 100 lost a further 1.5 percent near the close of European trading amid ongoing weakness in semiconductor titles, the European sector index fell by 1.3 percent. Salah-Eddine Bouhmidi, Head of Markets at broker IG, stated that skepticism toward the AI boom persists, noting that Nvidia's ongoing weakness weighs on confidence in the technology sector and that the willingness to take on risk after recent losses remains low.
At AI chip company Nvidia, the departure of chief executive Jensen Huang brings leadership questions into focus alongside a quarterly report scheduled for Tuesday after the market close. In addition, the market awaits the initial public offering of AI company Anthropic on Thursday.
Commodity stocks recorded losses at the start of the week due to falling precious and industrial metal prices, while shares in energy utilities pulled back from a rally lasting nearly four weeks.
In corporate developments, Italian bank Unicredit received approval from competition authorities in Brussels for its planned acquisition of Commerzbank. The European Commission stated there were no antitrust concerns regarding a merger, following an earlier approval from the US Federal Reserve. Unicredit shares declined 0.4 percent.
Defensive healthcare sector shares continued an upward trend supported by positive corporate news. Novo Nordisk rose 2.4 percent as one of the top performers in the Stoxx 50 index after the pharmaceutical company presented positive study data for its weight-loss drug CagriSema and received operational momentum from raised annual targets announced in early November. Novartis shares gained 1.3 percent to reach a record level after receiving a positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency for its drug Cosentyx to treat the chronic skin condition hidradenitis suppurativa.

